MycoMed Technologies
Pearl Diagnostics is dedicated to transforming diagnostics for lung infections by developing innovative in vitro diagnostic assays that detect circulating microbial extracellular vesicles, offering early and non-invasive detection methods. The company aims to support healthcare providers with clinical tools that improve patient outcomes, especially in immunocompromised populations and those with respiratory infections.
Industries
Nr. of Employees
small (1-50)
MycoMed Technologies
1812 Ashland Avenue, Ste. G32, Baltimore, MD 21205
Products
Urine ELISA assay for Aspergillus (96-well microplate)
A urine-based immunoassay configured as a 96-well ELISA kit for detection of Aspergillus-related urinary antigens; intended for early, non-invasive screening and laboratory testing.
Urine ELISA assay for Aspergillus (96-well microplate)
A urine-based immunoassay configured as a 96-well ELISA kit for detection of Aspergillus-related urinary antigens; intended for early, non-invasive screening and laboratory testing.
Services
Support services including troubleshooting, user training materials, and application support for laboratory and clinical users of urine diagnostic assays.
Commercial sales support and ordering information for diagnostic kit customers (note: products not available in the U.S.).
Support services including troubleshooting, user training materials, and application support for laboratory and clinical users of urine diagnostic assays.
Commercial sales support and ordering information for diagnostic kit customers (note: products not available in the U.S.).
Expertise Areas
- Urine-based infectious disease diagnostics
- Immunoassay development (antibody-based assays)
- Extracellular vesicle biomarker detection
- High-throughput ELISA kit manufacturing
Key Technologies
- Microplate ELISA (96-well)
- Lateral-flow / rapid immunoassay formats
- Monoclonal antibody-based detection
- Urinary antigen detection
News & Updates
The WHO highlights the growing risk of deadly fungi including Aspergillus fumigatus, Candida albicans, Candida auris, and Cryptococcus neoformans, emphasizing the need for improved diagnostics and treatments.
Pearl Diagnostics raised $3.5 million in seed funding to develop and commercialize a less invasive, rapid urine antigen test for fungal pneumonia, already approved in Europe and seeking FDA approval.
The company published a paper on urine antigen detection as an aid to diagnose invasive aspergillosis, collaborating with Johns Hopkins University.
The WHO highlights the growing risk of deadly fungi including Aspergillus fumigatus, Candida albicans, Candida auris, and Cryptococcus neoformans, emphasizing the need for improved diagnostics and treatments.
Pearl Diagnostics raised $3.5 million in seed funding to develop and commercialize a less invasive, rapid urine antigen test for fungal pneumonia, already approved in Europe and seeking FDA approval.
The company published a paper on urine antigen detection as an aid to diagnose invasive aspergillosis, collaborating with Johns Hopkins University.